BBOT · BridgeBio Oncology Therapeutics Inc
United States · RS rating 4 · As of 2026-11-03
| Price | 2.32 USD |
|---|---|
| 1-day change | +0.4% |
| RS rating (overall / 1M / 3M / 12M) | 4 / 9 / 3 / 9 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 28 / 5 / 36 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +52.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +83.1% |
| Market cap (USD) | $717.9M |